Medical News

RSS

FDA grants OsteoSymbionics 510(k) clearance for sterile processing of ClearShield cranial implant product

OsteoSymbionics, innovative designer and manufacturer of patient-specific craniofacial implants, is pleased to announce FDA (U.S. Food and Drug Administration) 510(k) clearance for sterile processing of its signature ClearShield™ cranial implant product, utilizing a novel room temperature peracetic acid/hydrogen peroxide (PAA) vacuum vapor sterilization process.

2 Jun 2014

Endo International subsidiary sells pharmaceutical drug discovery platform to AsanaBioSciences

Endo International plc today announced that its Endo Pharmaceuticals subsidiary has completed the sale of its branded pharmaceutical drug discovery platform to AsanaBioSciences, LLC, an independent member of the Amneal Alliance of Companies.

2 Jun 2014

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

2 Jun 2014

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

2 Jun 2014

Physicians Interactive eCoupon now available within Greenway Health's PrimeSUITE EHR system

Physicians Interactive, the leading provider of online and mobile clinical resources and solutions for healthcare professionals (HCPs), today announced that its eCoupon automated voucher and coupon distribution solution is now available within the latest version of Greenway Health's PrimeSUITE electronic health record (EHR) system.

2 Jun 2014

First Edition: June 2, 2014

Today's headlines include reports about state health law implementation activities as well as the next steps regarding the difficulties at the VA health system.

2 Jun 2014

Yale researchers find that hormone leptin may help treat metabolic disorders

Twenty years after the hormone leptin was found to regulate metabolism, appetite, and weight through brain cells called neurons, Yale School of Medicine researchers have found that the hormone also acts on other types of cells to control appetite.

2 Jun 2014

MESA, Curagita join forces to bring Diagnostic Imaging services to Germany

Medical Equipment Solutions and Applications, Europe's leader in multi-vendor service for Diagnostic Imaging systems, equipment and parts, and Heidelberg-based radiology management company Curagita are joining forces to bring new and broader solutions for a full range of Diagnostic Imaging services to the German healthcare market.

2 Jun 2014

Cherokee Health Systems selects NextGen Healthcare to provide RCM services

NextGen Healthcare Information Systems, LLC., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, announced today that Cherokee Health Systems has selected NextGen Healthcare to provide revenue cycle management (RCM) services to re-engineer its business processes, improve financial results and drive business growth.

2 Jun 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

$Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma$

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine.

2 Jun 2014

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis announced today the results of a pivotal Phase II trial demonstrating that patients with locally advanced (laBCC) or metastatic basal cell carcinoma (mBCC) taking the investigational oral compound LDE225 (sonidegib) had marked and sustained tumor shrinkage after a median follow-up of 13.9 months.

2 Jun 2014

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Many people with cystic fibrosis develop diabetes. The reasons for this have been largely unknown, but now researchers at Lund University in Sweden and  Karolinska institutet have identified a molecular mechanism that contributes to the raised diabetes risk.

2 Jun 2014

Updated data from ImmunoCellular ICT-107 trial in patients with newly diagnosed GBM presented at ASCO 2014

ImmunoCellular Therapeutics, Ltd. announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago.

2 Jun 2014

Compound in saliva may protect from toxins in tea, coffee and liquid smoke flavoring

A compound in saliva, along with common proteins in blood and muscle, may protect human cells from powerful toxins in tea, coffee and liquid smoke flavoring, according to results of a new study led by investigators at the Johns Hopkins Kimmel Cancer Center.

2 Jun 2014

New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group.

2 Jun 2014

Scientists use a flash of light to erase and restore memory

Using a flash of light, scientists have inactivated and then reactivated a memory in genetically engineered rats. The study, supported by the National Institutes of Health, is the first cause-and-effect evidence that strengthened connections between neurons are the stuff of memory.

2 Jun 2014

Risk of death following surgery is highest on weekends, in the afternoons and February

New research presented at this year's Euroanaesthesia show that on weekends, in the afternoons and in February are the times when the risk of death following surgery is the highest.

2 Jun 2014

Individuals who speak more languages may slow down cognitive decline from aging

New research reveals that bilingualism has a positive effect on cognition later in life. Findings published in Annals of Neurology, a journal of the American Neurological Association and Child Neurology Society, show that individuals who speak two or more languages, even those who acquired the second language in adulthood, may slow down cognitive decline from aging.

2 Jun 2014

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor.

2 Jun 2014

Medical News

FDA grants OsteoSymbionics 510(k) clearance for sterile processing of ClearShield cranial implant product

Endo International subsidiary sells pharmaceutical drug discovery platform to AsanaBioSciences

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Physicians Interactive eCoupon now available within Greenway Health's PrimeSUITE EHR system

First Edition: June 2, 2014

Yale researchers find that hormone leptin may help treat metabolic disorders

MESA, Curagita join forces to bring Diagnostic Imaging services to Germany

Cherokee Health Systems selects NextGen Healthcare to provide RCM services

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Updated data from ImmunoCellular ICT-107 trial in patients with newly diagnosed GBM presented at ASCO 2014

Compound in saliva may protect from toxins in tea, coffee and liquid smoke flavoring

New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

Scientists use a flash of light to erase and restore memory

Risk of death following surgery is highest on weekends, in the afternoons and February

Individuals who speak more languages may slow down cognitive decline from aging

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

Membrane proteins in focus: Turning high-risk targets into routine workflows

How metabolic phenotyping can detect viral infections in minutes

Directed enzyme evolution and the Nobel Prize: Making enzymes evolve in the lab

Latest News